 Phase 2: Phase 2 will last for 1 month and represents the time period of initiation of the study medication. Participants will be randomized to either 2 capsules of Theramine BID Group A or matching placebo Group B in a 1:1 treatment allocation. Subjects will take the study medications Theramine or placebo for the duration of this phase and complete daily headache diaries. Participants will also complete a Headache Impact Questionnaire HIT-6, which is a validated questionnaire to assess headache related disability in the last month. This phase will not be included in the data analysis as it may take 1 month to see a treatment effect after starting a preventative. 